Glaxo, First Genetic Trust in SNP Collaboration to Locate Adverse-Event Triggers | GenomeWeb

NEW YORK, Oct. 10 - GlaxoSmithKline and First Genetic Trust have entered into a broad SNP-related research collaboration to define why some individuals are susceptible to certain serious adverse events, the companies said on Wednesday.

GlaxoSmithKline will sponsor the study and conduct all analyses, while First Genetic Trust will provide its independent secure genetic banking services to store biological samples and medical data.

First Genetic Trust will also ensure that participating patients’ privacy is protected.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.